2. Academic Validation
  3. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

  • Mol Cancer Ther. 2015 Apr;14(4):931-40. doi: 10.1158/1535-7163.MCT-14-0833.
Paul Foster 1,  Kyoko Yamaguchi 1,  Pin P Hsu 1,  Fawn Qian 1,  Xiangnan Du 1,  Jianming Wu 1,  Kwang-Ai Won 1,  Peiwen Yu 1,  Christopher T Jaeger 1,  Wentao Zhang 1,  Charles K Marlowe 1,  Paul Keast 1,  Wendy Abulafia 1,  Jason Chen 1,  Jenny Young 1,  Artur Plonowski 1,  F Michael Yakes 1,  Felix Chu 1,  Kelly Engell 1,  Frauke Bentzien 1,  Sanh T Lam 1,  Stephanie Dale 1,  Olivia Yturralde 1,  David J Matthews 1,  Peter Lamb 1,  A Douglas Laird 2
Affiliations

Affiliations

  • 1 Exelixis, Inc., South San Francisco, California.
  • 2 Exelixis, Inc., South San Francisco, California. douglaslaird2000@yahoo.com.
PMID: 25637314 DOI: 10.1158/1535-7163.MCT-14-0833
Abstract

Dysregulation of PI3K/PTEN pathway components, resulting in hyperactivated PI3K signaling, is frequently observed in various cancers and correlates with tumor growth and survival. Resistance to a variety of Anticancer therapies, including receptor tyrosine kinase (RTK) inhibitors and chemotherapeutic agents, has been attributed to the absence or attenuation of downregulating signals along the PI3K/PTEN pathway. Thus, PI3K inhibitors have therapeutic potential as single agents and in combination with other therapies for a variety of Cancer indications. XL147 (SAR245408) is a potent and highly selective inhibitor of class I PI3Ks (α, β, γ, and δ). Moreover, broad kinase selectivity profiling of >130 protein kinases revealed that XL147 is highly selective for class I PI3Ks over other kinases. In cellular assays, XL147 inhibits the formation of PIP3 in the membrane, and inhibits phosphorylation of Akt, p70S6K, and S6 in multiple tumor cell lines with diverse genetic alterations affecting the PI3K pathway. In a panel of tumor cell lines, XL147 inhibits proliferation with a wide range of potencies, with evidence of an impact of genotype on sensitivity. In mouse xenograft models, oral administration of XL147 results in dose-dependent inhibition of phosphorylation of Akt, p70S6K, and S6 with a duration of action of at least 24 hours. Repeat-dose administration of XL147 results in significant tumor growth inhibition in multiple human xenograft models in nude mice. Administration of XL147 in combination with chemotherapeutic agents results in antitumor activity in xenograft models that is enhanced over that observed with the corresponding single agents.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16526
    99.69%, PI3K抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z